中国骨髓增生异常综合征患者TP53突变的特征及预后意义
该研究分析1219例中国骨髓增生异常综合征(MDS)患者,115例(9.4%)携带TP53异常,其中双等位基因异常占70.4%、单等位基因异常占29.6%。双等位基因突变者骨髓原始细胞升高(p < 0.001)、血小板计数降低(p = 0.007)且IPSS-R与IPSS-M危险度更高;双等位基因变异、复杂核型、-7、del(7q)及较高骨髓原始细胞与更差生存和更高急性髓系白血病(AML)转化风险相关,SF3B1突变为两个终点的保护因素。纵向测序显示AML转化期间可获得或克隆扩增TP53异常,12例达完全缓解(CR)患者中10例TP53突变不可测。
要点
- 115/1219例(9.4%)MDS患者携带TP53异常,双等位基因占70.4%、单等位基因占29.6%。
- 双等位基因变异、复杂核型、-7、del(7q)、较高骨髓原始细胞与更差生存和更高AML转化风险相关。
- TP53突变MDS中SF3B1突变为生存与AML转化的保护因素,12例CR患者中10例TP53突变不可测。
核心结论
- 中国MDS患者TP53突变特征与IWG-PM队列人群非常相似,TP53突变具有临床意义,治疗期间早期检测和动态监测TP53很重要。
研究设计与样本
- 研究分析1219例MDS患者,聚焦TP53突变者的临床与分子特征,并探究导致更差生存和疾病进展的因素。
主要发现
- 115例(9.4%)携带TP53异常,其中双等位基因异常占70.4%、单等位基因异常占29.6%。
- 双等位基因突变者骨髓原始细胞升高(p < 0.001)、血小板计数降低(p = 0.007),IPSS-R与IPSS-M危险度更高。
- 双等位基因变异、复杂核型、-7、del(7q)及较高骨髓原始细胞与TP53突变患者更差生存和更高AML转化风险相关。
- TP53突变MDS中SF3B1突变为生存与AML转化两个终点的保护因素。
- 纵向测序显示AML转化期间可获得或克隆扩增TP53异常;12例达CR患者中10例TP53突变不可测。
临床怎么用
- 作者指出,治疗期间早期检测和动态监测TP53很重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumour protein p53 (TP53) mutations occur frequently in myelodysplastic syndromes (MDS) and are associated with a high risk of treatment failure and adverse outcomes. In this study, we analysed 1219 patients with MDS, focusing on the clinical and molecular characteristics of those with TP53 mutations and investigating factors contributing to worse survival and disease progression. One hundred and fifteen (9.4%) patients carried TP53 alterations, of which 70.4% had biallelic and 29.6% had monoallelic alterations. Individuals with biallelic mutations showed elevated bone marrow (BM) blasts (p < 0.001), decreased platelet counts (p = 0.007) and higher the Revised International Prognostic Scoring System (IPSS-R) and Molecular International Prognostic Scoring System (IPSS-M) categories. The biallelic variants, complex karyotype, -7, del(7q) and higher BM blast were linked to worse survival and a higher risk of acute myeloid leukaemia (AML) transformation in TP53-mutated patients. SF3B1 mutations were protective factors for both end-points within TP53-mutated MDS. These characteristics are very similar to populations from the International Working Group for the Prognosis of MDS (IWG-PM) cohort. By performing longitudinal sequencing, we revealed the acquisition or clonal amplification of TP53 alterations during AML transformation. We also conducted repeated sequencing in patients who achieved complete remission (CR) and observed that TP53 mutations were undetectable in 10 of 12 patients. Our findings revealed the clinical significance of TP53 mutations in MDS and highlighted the importance of early detection and dynamic monitoring of TP53 during treatment.
引用
- Huang N, Chang C, Wu L, et al. Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes. Br J Haematol. 2025. PMID: 40755402. doi:10.1111/bjh.70078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。